GLP-1 RAs enhance autophagy through coordinated AMPK activation and partial mTORC1 inhibition, promoting the formation of autophagosomes that engulf damaged organelles and protein aggregates [44,45]
The difference is small because elimination is logarithmic, not linear
Furthermore, despite the 5 % weight loss at week nine, subjects taking inulin ate significantly less (~270 kcal less, p = 0.027) at the follow-up ad libitum meal, with no consequent rebound in food intake at the 18 week visit despite a total 7 % weight loss in the inulin group, suggesting that inulins effect on weight management is mediated via appetite modulation
In a follow-up editorial to the New England Journal of Medicine Study, David Standaert MD PhD from the University of Alabama commented that, Although a variety of physiological effects are observed in response to GLP-1 receptor activation, a consistent finding is reduced inflammation in the brain, a process that is central to the pathophysiology of Parkinsons disease. Have there been other trials of GLP-1 drugs in Parkinsons disease besides Lixisenatide
Q2: Do you provide COA and lab test reports?A2: Yes, we provide Certificate of Analysis (COA), lab test reports, and MSDS upon request
